The effect of alpha-lipoic acid on migraine.

The effects of alpha-lipoic acid supplementation on oxidative stress status, inflammatory markers, VCAM-I serum levels, lactate and clinical symptoms in women with migraine.

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20161203031212N3

Enrollment

Registered

2020-11-09

Start date

2020-10-22

Completion date

Unknown

Last updated

2021-04-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

migraine. Migraine without aura

Interventions

Intervention 1: People will receive 300 mg of alpha-lipoic acid supplement twice a day for 3 months. The supplement and placebo will be provided by Raha Pharmaceutical Company. Intervention 2: The con

Eligibility

Sex/Gender

Female

Age

20 Years to 50 Years

Inclusion criteria

Inclusion criteria: Willingness to participation in the study. Diagnosis of migraine by a neurologist based on ICHD-3 criteria. Age 20 to 50 years. Non-menopausal women.

Exclusion criteria

Exclusion criteria: History of any allergies, intolerances or adverse drug reactions to the supplement. Pregnancy and lactation. History of intestinal bypass. Follow a special diet for the past 6 months. Smoking or alcohol. Take any supplements. Cardiovascular disease, diabetes, liver, kidney, thyroid, malignant disease and other neurological disorders are diagnosed based on the patient interview. Start taking the new drug within the last 1 month

Design outcomes

Primary

Measure	Time frame
Migraine severity. Timepoint: At baseline and after 3 month. Method of measurement: Visual analogue scale.;Migraine frequency . Timepoint: At baseline and after 3 month. Method of measurement: Clinical examination.;Migraine duration. Timepoint: At baseline and after 3 month. Method of measurement: Clinical examination.;Headache impact test. Timepoint: At baseline and after 3 month. Method of measurement: HIT questionnaire.;C-reactive protein (CRP). Timepoint: At baseline and after 3 month. Method of measurement: Colorimetric method.;Serum glutathion. Timepoint: At baseline and after 3 month. Method of measurement: Colorimetric method.;Total antioxidant capacity. Timepoint: At baseline and after 3 month. Method of measurement: Colorimetric method.;Total oxidant capacity. Timepoint: At baseline and after 3 month. Method of measurement: Colorimetric method.;Malondialdehyde. Timepoint: At baseline and after 3 month. Method of measurement: Colorimetric method.	—

Measure

Time frame

Migraine severity. Timepoint: At baseline and after 3 month. Method of measurement: Visual analogue scale.;Migraine frequency . Timepoint: At baseline and after 3 month. Method of measurement: Clinical examination.;Migraine duration. Timepoint: At baseline and after 3 month. Method of measurement: Clinical examination.;Headache impact test. Timepoint: At baseline and after 3 month. Method of measurement: HIT questionnaire.;C-reactive protein (CRP). Timepoint: At baseline and after 3 month. Method of measurement: Colorimetric method.;Serum glutathion. Timepoint: At baseline and after 3 month. Method of measurement: Colorimetric method.;Total antioxidant capacity. Timepoint: At baseline and after 3 month. Method of measurement: Colorimetric method.;Total oxidant capacity. Timepoint: At baseline and after 3 month. Method of measurement: Colorimetric method.;Malondialdehyde. Timepoint: At baseline and after 3 month. Method of measurement: Colorimetric method.

—

Secondary

Measure	Time frame
Vascular cell adhesion molecule-1. Timepoint: At baseline and after 3 month. Method of measurement: It will be measured by ELISA kit.;Serum lactate. Timepoint: At baseline and after 3 month. Method of measurement: Colorimetric method.;Serum Nitric Oxide. Timepoint: At baseline and after 3 month. Method of measurement: Colorimetric method.;Depression. Timepoint: At baseline and after 3 month. Method of measurement: DASS questionnaire.;Anxiety. Timepoint: At baseline and after 3 month. Method of measurement: DASS questionnaire.;Stress. Timepoint: At baseline and after 3 month. Method of measurement: DASS questionnaire.	—

Measure

Time frame

Vascular cell adhesion molecule-1. Timepoint: At baseline and after 3 month. Method of measurement: It will be measured by ELISA kit.;Serum lactate. Timepoint: At baseline and after 3 month. Method of measurement: Colorimetric method.;Serum Nitric Oxide. Timepoint: At baseline and after 3 month. Method of measurement: Colorimetric method.;Depression. Timepoint: At baseline and after 3 month. Method of measurement: DASS questionnaire.;Anxiety. Timepoint: At baseline and after 3 month. Method of measurement: DASS questionnaire.;Stress. Timepoint: At baseline and after 3 month. Method of measurement: DASS questionnaire.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Amir Mansour Alavi

Esfahan University of Medical Sciences

am.alavi@nutr.mui.ac.ir+98 31 3792 3154

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026